---
title: "Lanifibranor (IVA337) in Metabolic dysfunction-associated steatohepatitis with F2 to F3 fibrosis: Heterogeneity of treatment effect"
description: "Formulary evidence on Lanifibranor (IVA337) in Metabolic dysfunction-associated steatohepatitis with F2 to F3 fibrosis: Heterogeneity of treatment effect. Topics: NATIVE: histologic response in participants with type 2 diabetes, NATIVE: race of participants and applicability to other racial and ethnic groups, NATIVE: response by type 2 diabetes status and fibrosis stage F2 to F3 (company presentation), NATIVE and other phase 2 studies: metabolic response by type 2 diabetes status (descriptive comparison), and 7 further topics. 11 evidence topics quoted from 10 sources."
canonical: "https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis/product-information-and-disease-description/heterogeneity-of-treatment-effect"
published: "2026-11-18T22:34:49-05:00"
modified: "2026-11-18T22:34:49-05:00"
---

# Lanifibranor (IVA337) in Metabolic dysfunction-associated steatohepatitis with F2 to F3 fibrosis: Heterogeneity of treatment effect

<a id="heading-2.2.2.3"></a>

## 2.2.2.3 Heterogeneity of Treatment Effect

<a id="topic-2.2.2.3-1"></a>

### NATIVE: histologic response in participants with type 2 diabetes

> “A total of 103 patients who underwent randomization had type 2 diabetes mellitus; the mean age of these patients was 56 years, the mean body-mass index was 33, 62 (60%) were women, 83 (81%) had significant or advanced fibrosis, and 84 (82%) had an NAS of 6 or greater.”
> “The patients with diabetes had improvements in histologic features of NASH that were similar to those in the full analysis population, and they had more pronounced reductions in fasting levels of glucose, insulin, and glycated hemoglobin than those observed in the full analysis population.”
> “Lanifibranor appeared to improve histologic features in patients regardless of diabetes status.”

Source: [Francque et al. (2021)](https://www.nejm.org/doi/full/10.1056/NEJMoa2036205)

<a id="topic-2.2.2.3-2"></a>

### NATIVE: race of participants and applicability to other racial and ethnic groups

> “The mean age of the patients was 54 years, and the mean body-mass index (the weight in kilograms divided by the square of the height in meters) was 33; 144 (58%) were female, 232 (94%) were White, and 103 (42%) had type 2 diabetes mellitus.”
> “The majority of patients in this 24-week trial were White. To assess whether longer treatment would result in similar efficacy and whether this efficacy would apply to other racial and ethnic groups, some of which have a greater predisposition to NASH than others, an appropriate phase 3 trial of longer duration and with more extensive assessments for efficacy and safety is needed.”

Source: [Francque et al. (2021)](https://www.nejm.org/doi/full/10.1056/NEJMoa2036205)

<a id="topic-2.2.2.3-3"></a>

### NATIVE: response by type 2 diabetes status and fibrosis stage F2 to F3 (company presentation)

> “Resolution of MASH and improvement of fibrosis: effect size is increased in F2/F3 patients as well as patients with T2D”
> “Fibrosis improvement and MASH resolution rates were higher in patients with T2D.”
> “With lanifibranor: 21% (800 mg) and 26% (1200 mg) in T2D vs 7% and 22% in non-T2D.”

Source: [Inventiva investor and analyst day presentation (2025)](https://inventivapharma.com/wp-content/uploads/Inventiva-Investor-and-Analyst-Day-10-08-2025.pdf)

<a id="topic-2.2.2.3-4"></a>

### NATIVE and other phase 2 studies: metabolic response by type 2 diabetes status (descriptive comparison)

> “Metabolic benefits of lanifibranor were seen in these studies regardless of T2DM diagnosis”
> “Glycemic improvement scales with baseline burden and is greatest in established T2DM.”
> “Comparisons were descriptive, without statistical pooling.”
> “Absolute glycaemic gains are larger where baseline burden is higher (T2DM), while the adiponectin (PPARγ-engagement) response is essentially identical across strata.”

Source: [Holleboom et al. (2026)](https://inventivapharma.com/wp-content/uploads/Metabolic-Benefits-of-Lanifibranor-in-Patients-With-and-Without-Type-2-Diabetes_ParisMASH_poster.pdf)

<a id="topic-2.2.2.3-5"></a>

### NATIVE retrospective analysis: response by PNPLA3 I148M genotype

> “Of these, 219 patients consented to genotyping for the PNPLA3 rs738409 SNP. Sixty five were II, 105 IM and 49 MM, which is highest risk for disease severity and progression.”
> “There was no significant difference in response to lanifibranor by PNPLA3 genotype, despite the fact that MM genotype patients had more activity on biopsy than the II or IM patients (82% NAS≥6, vs 74%, 70%), while there was no difference in fibrosis.”
> “The efficacy of lanifibranor on both liver histology and markers of cardiometabolic health appears to be independent of PNPLA3 status, despite MM genotype patients having more severe activity on liver biopsy.”

Source: [Griffel et al. (2023)](https://inventivapharma.com/wp-content/uploads/inventiva-documents/Poster-AASLD23-PNPLA3_V1.0_20231013.pdf)

<a id="topic-2.2.2.3-6"></a>

### NATIVE post hoc analysis: response by weight change during treatment

> “Patients were stratified by BL ADP level (< 5, 5–10, > 10 µg/mL) and by fold-change at EOT (< 1.5x, 1.5–4x, > 4x) and weight change (≤ 2.5%, 2.5–5% and > 5%).”
> “These effects were independent of body-weight change. Although modest weight gain was observed with lanifibranor, it did not prevent improvement in MASH, fibrosis, or cardiometabolic parameters.”

Source: [Rinella et al. (2026b)](https://inventivapharma.com/wp-content/uploads/ADP-and-Weight-Gain-Correlation-Poster_EASL2624.pdf)

<a id="topic-2.2.2.3-7"></a>

### NATIVE biomarker analysis: serum signatures of histologic response to lanifibranor

> “Patients receiving lanifibranor were pooled, and those with liver biopsies were selected (n = 142).”
> “These signatures provided good accuracy for the noninvasive identification of histologic response under lanifibranor with area under the receiver operating characteristic curve at 0.81 ± 0.08 for E1 score, 0.80 ± 0.08 for E2 score, and 0.81 ± 0.08 for E3 score.”
> “These findings support utilizing a similar approach in a larger sample size (NATiV3, NCT03008070).”

Source: [Boursier et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/40107637/)

<a id="topic-2.2.2.3-8"></a>

### Comparator therapies: resmetirom response in participants receiving background GLP-1 RA therapy

> “GLP-1 RA treated patients showed similar rates of MASH resolution and fibrosis improvement in combination with resmetirom as patients not on these therapies and no notable differences in safety and tolerability were observed.”

Source: [Bansal et al. (2026)](https://journals.lww.com/hep/fulltext/10.1097/hep.0000000000001608~semaglutide-therapy-for-metabolic-dysfunctionassociated)

<a id="topic-2.2.2.3-9"></a>

### Comparator therapies: tirzepatide histologic response and metabolic change by type 2 diabetes status (SYNERGY-NASH post hoc analysis)

> “Few MASH studies have compared histological responses in participants with T2D with those who do not have T2D.”
> “In participants included in the present analyses, placebo-adjusted body weight reduction with tirzepatide 15 mg was nonsignificantly (P = 0.128 for interaction term) lower in participants with T2D (−14.5%) versus those without T2D (−22.5%).”
> “However, the association between fibrosis improvement response and changes in metabolic parameters such as HbA1c, body weight, and adiponectin were driven mainly by significant associations in the T2D group and were not observed in the non-T2D group.”

Source: [Caussy et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12635880/)

<a id="topic-2.2.2.3-10"></a>

### Comparator therapies: dapagliflozin response by age and sex (DEAN)

> “Thirdly, a high proportion of male and relatively younger participants were recruited in this trial because they may be more willing to accept liver biopsy at screening. Although the results showed no age and sex differences of dapagliflozin on MASH improvement, female and the older patients were underrepresented in the current study.”

Source: [Lin et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12135075/)

<a id="topic-2.2.2.3-11"></a>

### Comparator therapies: bariatric surgery histologic response in Asian countries

> “Interestingly, the percentage of individuals with improved steatosis and hepatic fibrosis was higher in Asian countries.”

Source: [European Association for the Study of the Liver (2024)](https://www.journal-of-hepatology.eu/article/S0168-8278%2824%2900329-5/fulltext)

## Related pages
- [Lanifibranor (IVA337): Metabolic dysfunction-associated steatohepatitis with F2 to F3 fibrosis](https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis) · [Markdown](https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis.md)
- [Lanifibranor (IVA337) in Metabolic dysfunction-associated steatohepatitis with F2 to F3 fibrosis: Terms and abbreviations](https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis/terms-and-abbreviations.md)
- [Lanifibranor (IVA337): Metabolic dysfunction-associated steatohepatitis with F2 to F3 fibrosis](https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis/executive-summary) · [Markdown](https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis/executive-summary.md)
- [Lanifibranor (IVA337) in Metabolic dysfunction-associated steatohepatitis with F2 to F3 fibrosis: Product information and disease description](https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis/product-information-and-disease-description.md)
- [Lanifibranor (IVA337) in Metabolic dysfunction-associated steatohepatitis with F2 to F3 fibrosis: Clinical evidence](https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis/clinical-evidence.md)
- [Lanifibranor (IVA337) in Metabolic dysfunction-associated steatohepatitis with F2 to F3 fibrosis: Economic information and modeling report](https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis/economics) · [Markdown](https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis/economics.md)
- [Lanifibranor (IVA337) in Metabolic dysfunction-associated steatohepatitis with F2 to F3 fibrosis: References](https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis/references) · [Markdown](https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis/references.md)
